Federated Hermes, Inc. Rigel Pharmaceuticals Inc Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $40,667 - $61,518	-17,232 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $60,308 - $77,539	17,231 Added 1723100.0%	17,232 $63,000
Q2 2021 Aug 16, 2021	SELL	$3.09 - $4.54 $404 - $594	-131 Reduced 99.24%	1 $1,000
Q1 2021 May 13, 2021	BUY	$3.35 - $4.93 $442 - $650	132 New	132 $1,000
Q3 2018 Nov 13, 2018	SELL	$2.6 - $3.59 $33,529 - $46,296	-12,896 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$2.83 - $4.11 $36,495 - $53,002	12,896 New	12,896 $36,000
Q1 2018 May 09, 2018	SELL	$3.54 - $4.54 $1,794 - $2,301	-507 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $1,637 - $2,180	507	507 $0

345K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $4.75B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.